MA
GSK icon

Montag & Associates’s GSK GSK Stock Holding History

Montag & Associates’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$118K Sell
2,222
-10
-0.4% -$529 0.01% 489
2026
Q1 		$124K Sell
2,232
-102
-4% -$5.53K 0.01% 483
2025
Q4 		$115K Sell
2,334
-111
-5% -$5.18K 0.01% 488
2025
Q3 		$107K Buy
2,445
+35
+1% +$1.37K ﹤0.01% 482
2025
Q2 		$93.6K Hold
2,410
– – ﹤0.01% 488
2025
Q1 		$94.3K Buy
2,410
+42
+2% +$1.54K ﹤0.01% 506
2024
Q4 		$80.9K Sell
2,368
-305
-11% -$11K ﹤0.01% 536
2024
Q3 		$110K Hold
2,673
– – 0.01% 492
2024
Q2 		$104K Sell
2,673
-240
-8% -$10.1K 0.01% 489
2024
Q1 		$126K Hold
2,913
– – 0.01% 464
2023
Q4 		$109K Sell
2,913
-800
-22% -$28.7K 0.01% 464
2023
Q3 		$135K Buy
3,713
+35
+1% +$1.24K 0.01% 430
2023
Q2 		$132K Hold
3,678
– – 0.01% 445
2023
Q1 		$132K Sell
3,678
-960
-21% -$33.6K 0.01% 436
2022
Q4 		$165K Buy
4,638
+274
+6% +$9.13K 0.01% 396
2022
Q3 		$130K Sell
4,364
-1
-0% -$38 0.01% 413
2022
Q2 		$239K Buy
4,365
+721
+20% +$39.8K 0.02% 341
2022
Q1 		$198K Hold
3,644
– – 0.01% 391
2021
Q4 		$201K Hold
3,644
– – 0.01% 385
2021
Q3 		$174K Hold
3,644
– – 0.01% 402
2021
Q2 		$181K Hold
3,644
– – 0.01% 402
2021
Q1 		$163K Hold
3,644
– – 0.01% 416
2020
Q4 		$168K Buy
+3,644
New +$167K 0.01% 383
2018
Q3 		– Sell
-4,524
Closed -$228K – 325
2018
Q2 		$228K Hold
4,524
– – 0.02% 264
2018
Q1 		$221K Buy
+4,524
New +$211K 0.02% 266
2014
Q3 		– Sell
-3,432
Closed -$229K – 242
2014
Q2 		$229K Hold
3,432
– – 0.04% 233
2014
Q1 		$229K Hold
3,432
– – 0.04% 218
2013
Q4 		$229K Hold
3,432
– – 0.04% 209
2013
Q3 		$215K Buy
+3,432
New +$221K 0.04% 210

Other funds holding GSK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Montag & Associates's GSK Position: Q2 2026 in Review

Montag & Associates reduced its GSK (GSK) stake by 0.45% in Q2 2026, selling an estimated $529 and leaving 2,222 shares worth $118K. The position accounts for 0.01% of the portfolio, ranked #489.

Montag & Associates first reported a position in GSK in Q3 2013 and has held it in 29 quarters since. The position peaked at $239K in Q2 2022. 1,045 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

  • Montag & Associates held 2,222 shares of GSK worth $118K as of Q2 2026.
  • Montag & Associates sold 10 GSK shares in Q2 2026, an estimated $529.
  • GSK made up 0.01% of Montag & Associates's portfolio in Q2 2026, its #489 holding.
  • Montag & Associates first reported a position in GSK in Q3 2013 and has held it in 29 quarters since.
  • Montag & Associates's GSK position peaked at $239K in Q2 2022.
  • 1,045 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Montag & Associates's 13F filing for Q2 2026, filed 5 Aug 2026.